Trials / Completed
CompletedNCT03014635
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines (SAKURA-2)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 306 (actual)
- Sponsor
- Revance Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Botulinum Toxins, Type A | Intramuscular injection |
| BIOLOGICAL | Placebos | Intramuscular injection |
Timeline
- Start date
- 2016-12-05
- Primary completion
- 2017-11-03
- Completion
- 2017-11-03
- First posted
- 2017-01-09
- Last updated
- 2022-07-21
- Results posted
- 2022-07-21
Locations
14 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT03014635. Inclusion in this directory is not an endorsement.